MIH
IBB icon

Meitav Investment House’s iShares Biotechnology ETF IBB Stock Holding History

Meitav Investment House’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,049
Closed -$2.04M – 274
2023
Q4 		$2.04M Sell
15,049
-279
-2% -$34K 0.03% 151
2023
Q3 		$1.9M Sell
15,328
-47
-0.3% -$5.98K 0.03% 161
2023
Q2 		$1.93M Sell
15,375
-102
-0.7% -$13.3K 0.03% 180
2023
Q1 		$2.03M Sell
15,477
-7,970
-34% -$1.04M 0.04% 178
2022
Q4 		$3.09M Sell
23,447
-113
-0.5% -$14.6K 0.05% 163
2022
Q3 		$2.77M Sell
23,560
-140
-0.6% -$17.4K 0.05% 175
2022
Q2 		$2.79M Sell
23,700
-7,020
-23% -$833K 0.05% 172
2022
Q1 		$4M Sell
30,720
-218
-0.7% -$28.4K 0.06% 175
2021
Q4 		$4.72M Sell
30,938
-160
-0.5% -$24.8K 0.08% 162
2021
Q3 		$5.03M Sell
31,098
-7,025
-18% -$1.18M 0.08% 157
2021
Q2 		$6.24M Buy
38,123
+6,728
+21% +$1.04M 0.16% 113
2021
Q1 		$4.73K Buy
31,395
+11,418
+57% +$1.81M 0.13% 124
2020
Q4 		$3.02M Buy
19,977
+2,231
+13% +$319K 0.12% 108
2020
Q3 		$2.4M Buy
17,746
+14,134
+391% +$1.92M 0.12% 102
2020
Q2 		$494K Buy
+3,612
New +$460K 0.03% 225
2020
Q1 		– Sell
-1,941
Closed -$234K – 411
2019
Q4 		$234K Sell
1,941
-4,109
-68% -$458K 0.02% 376
2019
Q3 		$609K Sell
6,050
-6,074
-50% -$636K 0.04% 220
2019
Q2 		$1.32M Buy
12,124
+320
+3% +$34K 0.09% 130
2019
Q1 		$1.32M Buy
11,804
+7,950
+206% +$872K 0.07% 156
2018
Q4 		$341K Sell
3,854
-4,564
-54% -$484K 0.02% 242
2018
Q3 		$1.02M Sell
8,418
-3,379
-29% -$398K 0.05% 207
2018
Q2 		$1.55M Sell
11,797
-68,502
-85% -$7.33M 0.07% 153
2018
Q1 		$8.57M Sell
80,299
-429,842
-84% -$47.6M 0.44% 61
2017
Q4 		$54.5M Buy
+510,141
New +$54.5M 3.18% 7

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Meitav Investment House's IBB Position: Q1 2024 in Review

Meitav Investment House sold out of iShares Biotechnology ETF (IBB) in Q1 2024, closing a stake of 15,049 shares — an estimated $2.04M sold.

Meitav Investment House first reported a position in IBB in Q4 2017 and held it in 24 quarters. The position peaked at $54.5M in Q4 2017. 899 funds tracked by Wall St. Rank hold IBB as of Q1 2024.

  • Meitav Investment House reported no remaining iShares Biotechnology ETF position as of Q1 2024 after selling out during the quarter.
  • Meitav Investment House sold 15,049 iShares Biotechnology ETF shares in Q1 2024, an estimated $2.04M.
  • Meitav Investment House first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 24 quarters.
  • Meitav Investment House's iShares Biotechnology ETF position peaked at $54.5M in Q4 2017.
  • 899 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2024.

Based on Meitav Investment House's 13F filing for Q1 2024, filed 1 May 2024.